Clinical Trial

Thermal Spa Treatment and Improvement of Primary Ciliary Dyskinesia

Study acronym: CANDY
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate whether a 3-week thermal spa treatment can improve quality of life and reduce ENT (ear, nose, and throat) symptoms in adults with Primary Ciliary Dyskinesia (PCD). PCD is a rare, chronic condition that affects the airways and often leads to persistent sinus, ear, and lung infections. The main questions the study aims to answer are: Does spa therapy improve ENT-related symptoms and daily quality of life? Does it help reduce the frequency of infections and the need for antibiotics? Are there improvements in hearing and lung function? In this study, participants will be randomly assigned to one of two groups: Group A will begin with a 3-week spa treatment, followed by regular checkups for 6 months. Group B will start with standard care for 6 months, then receive the spa treatment and follow-up evaluations for another 6 months. All participants will: Undergo ENT and lung function evaluations (questionnaires, hearing tests, nasal swabs, spirometry) Visit one of two spa centers for a 3-week treatment period (without hospital stay) Be followed regularly over several months for checkups and tests Researchers will compare participants' symptoms and test results before and after the spa treatment to determine its benefits. Potential benefits: Participants may experience relief from nasal symptoms, fewer respiratory infections, improved hearing and breathing, and an overall better quality of life. Potential risks: There is a small risk of infection from a new germ or a mild, short-term flare-up of chronic symptoms (called a "thermal reaction") that can occur during spa therapy.
Trial Details
NCT Number NCT07029594
Lead Sponsor Association Francaise pour la Recherche Thermale
Collaborators: Centre Antoine Lacassagne
Conditions Primary Ciliary Dyskinesia
Enrollment 35 participants
Start Date 2025-09-05
Primary Completion 2026-12-05 (estimated)
Study Completion 2027-05-05 (estimated)
Updated on ClinicalTrials.gov 2025-06-19